卵巢癌易早期转移并对化疗耐药,导致5年生存率无明显提高。研究证实酪氨酸蛋白激酶(PTK)在多种肿瘤中呈现高表达和高活性。许多受体型PTK(RPTK)和非受体型PTK由于基因扩增或结构异常改变,诱导PTK活性增高,通过多条信号途径,最终促进卵巢恶性肿瘤的生长和转移,并诱导耐药性产生。PTK抑制剂具有抑制增殖和化疗增敏作用,在抗肿瘤治疗中有潜在的应用价值。 Early ovarian cancer metastasis and resistance to chemotherapy, resulting in no significant increase in 5-year survival. Studies have shown that tyrosine protein kinase (PTK) in a variety of tumors showed high expression and high activity. Many receptor type PTK (RPTK) and non-receptor type PTK induce PTK activity increase due to gene amplification or structural abnormalities, and ultimately promote the growth and metastasis of ovarian malignant tumors through multiple signal pathways and induce drug resistance . PTK inhibitors inhibit proliferation and chemosensitization, and have potential application in anti-tumor therapy.